The IDEAL study: Towards personalized drug treatment of hypertension

Therapie

Volumn 67, Issue 3, 2012, Pages 195-204

  Bejan Angoulvant, Theodora ^a,b,c   Baguet, Jean Philippe ^d,e   Erpeldinger, Sylvie ^c   Boivin, Jean Marc ^f,g   Mercier, Alain ^h,i   Leftheriotis, Georges ^j   Gagnol, Jean Pierre ^k   Fauvel, Jean Pierre ^l   Giraud, Céline ^a   Bricca, Giampiero ^a   Gueyffier, François ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b CNRS   (France)

^c UNIVERSITÉ LYON 1   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e French Clinical Research Infrastructure Network   (France)

^f INSERM   (France)

^g UNIVERSITÉ DE LORRAINE   (France)

^h UNIVERSITÉ DE ROUEN   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j ANGERS UNIVERSITY HOSPITAL   (France)

^k HÔPITAL ARNAUD DE VILLENEUVE   (France)

^l EDOUARD HERRIOT HOSPITAL   (France)

more..

Author keywords

Drug treatment; Hypertension; Pharmacogenetics; Responders; Treatment response biomarkers

Indexed keywords

GLYCINE; INDAPAMIDE; PERINDOPRIL; PLACEBO; TRYPTOPHAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; HEREDITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHENOTYPE; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84865228735     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2012031     Document Type: Article

References (43)

1. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: Improving the estimate of therapeutic benefit. J Hum Hypertens 1996; 10(1): 1-8
2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665
3. Gueyffier F, Boutitie F, Boissel JP, et al. Indana: A meta-analysis on individual patient data in hypertension. Protocol and preliminary results. Therapie 1995; 50: 353-62
4. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm hg. JAMA 1970; 213: 1143-52
5. Veterans administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm hg. JAMA 1967; 202: 1028-34
6. Post-stroke antihypertensive treatment study. A preliminary result. Pats collaborating group. Chin Med J (Engl) 1995; 108: 710-7
7. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41
8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145-53
9. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007; 370: 829-40
10. Neal B, MacMahon S, Chapman N. Effects of ace inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. Lancet 2000; 356: 1955-64
11. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Hot study group. Lancet 1998; 351: 1755-62
12. Principal results of the japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31: 2115-27
13. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80 years and older: The lower the better? A metaanalysis of randomized controlled trials. J Hypertens 2010; 28: 1366-72
14. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
15. Boissel JP, Gueyffier F, Boutitie F, et al. Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundam Clin Pharmacol 2005; 19: 579-84
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001; 358: 1305-15
17. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
18. Gueyffier F, Boutitie F, Cornu C, et al. Presentation of octave II. A current epidemiologic study in france of the added prognostic value of ambulatory blood pressure monitoring. Arch Mal Coeur Vaiss 1996; 89: 1381-8
19. Bell KJ, Hayen A, Macaskill P, et al. Monitoring initial response to angiotensin-converting enzyme inhibitor-based regimens: An individual patient data meta-analysis from randomized, placebo-controlled trials. Hypertension 2010; 56: 533-9
20. Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: A computer simulation study. Am J Hypertens 2008; 21: 85-91
21. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of veterans affairs cooperative study group on antihypertensive agents. N Engl J Med 1993; 328: 914-21
22. Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13
23. Attwood S, Bird R, Burch K, et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994; 12: 1053-60
24. Johnson JA, Boerwinkle E, Zineh I, et al. Pharmacogenomics of antihypertensive drugs: Rationale and design of the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J 2009; 157: 442-9
25. Turner ST, Schwartz GL, Chapman AB, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010; 23: 1014-22
26. Morgan TO, Anderson AI, MacInnis RJ. Ace inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14: 241-7
27. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7
28. Kurland L, Melhus H, Karlsson J, et al. On behalf of the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19: 1783-7
29. Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (arg389gly) affects blood pressure response to betablockade. Clin Pharmacol Ther 2003; 73: 366-71
30. van Rijn-Bikker PC, Mairuhu G, van Montfrans GA, et al. Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. Am J Hypertens 2009; 22: 1295-302
31. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: Initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (the GENRES study). Am J Hypertens 2007; 20: 311-8
32. Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, et al. Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: Results from the randomized, double-blind, crossover GENRES study. J Hypertens 2008; 26: 1250-6
33. Suonsyrja T, Donner K, Hannila-Handelberg T, et al. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics 2010; 20: 342-5
34. Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J Hypertens 2005; 23: 1311-25
35. Arnett DK, Claas SA, Lynch AI. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension̊ Curr Opin Cardiol 2009; 24: 333-9
36. Johnson JA. Pharmacogenomics of antihypertensive drugs: Past, present and future. Pharmacogenomics 2010; 11: 487-91
37. Suonsyrja T, Donner K, Hannila-Handelberg T, et al. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. Pharmacogenet Genomics 2010; 20: 342-5
38. Ribba B, Tracqui P, Boix JL, et al. QxDB: A generic database to support mathematical modelling in biology. Philos Transact A Math Phys Eng Sci 2006; 364: 1517-32
39. Thomas SR, Baconnier P, Fontecave J, et al. Saphir: A physiome core model of body fluid homeostasis and blood pressure regulation. Philos Transact A Math Phys Eng Sci 2008; 366: 3175-97
40. Fenner JW, Brook B, Clapworthy G, et al. The EuroPhysiome, STEP and a roadmap for the virtual physiological human. Philos Transact A Math Phys Eng Sci 2008; 366: 2979-99
41. Hunter P, Coveney PV, de Bono B, et al. A vision and strategy for the virtual physiological human in 2010 and beyond. Philos Transact A Math Phys Eng Sci 2010; 368: 2595-614
42. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-97
43. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009: CD004349